HER4 in breast cancer: comparison of antibodies against intra- and extra-cellular domains of HER4.
BACKGROUND
We have previously linked HER4 expression with increased survival in breast cancer. However, other reports have associated HER4 with adverse prognostic significance. One possible explanation for the conflicting reports may be that these results are antibody dependent. The HER4 protein is enzymatically cleaved, which may alter the function of its intracellular domain (ICD). We have therefore compared the staining patterns of antibodies against its intracellular and extracellular domains using tissue microarray technology.


METHODS
Immunohistochemistry was performed and evaluated on tumours from 402 tamoxifen treated oestrogen receptor positive patients. The HFR1 antibody recognises the ICD of HER4 and thus recognises both the intact receptor and the cleaved ICD. The H4.77.16 clone recognises an extracellular domain of HER4 and thus detects the full length receptor only.


RESULTS
Both antibodies demonstrated nuclear, cytoplasmic and membranous staining. Concordance between the membrane staining patterns was high (88.44%, kappa 0.426). The HFR1 antibody, however, demonstrated generally higher levels of cytoplasmic staining (concordance 74.77%, kappa 0.351). The antibodies demonstrated very different patterns of nuclear staining. Over 60% of patients stained with the H4.77.16 had no nuclear staining whereas the vast majority showed staining with the HFR1 antibody (concordance 40.12%, kappa 0.051). Neither antibody demonstrated relationships between membranous or cytoplasmic HER4 staining and survival, although associations were seen with known poor prognostic markers. Cases with H4.77.16-determined nuclear staining had significantly poorer survival outcomes.


CONCLUSIONS
The difference in antigen site may explain the different staining patterns we have seen with respect to location; with each antibody appearing to select for distinct compartments. Thus, HFR1 may select for cytoplasmic and nuclear HER4 ICD, whilst H4.77.16 selects for membranous HER4 and/or HER4 being recycled in cytoplasm or nucleus. This ability to distinguish between site and function of HER4 and its fragments is particularly important, with recent evidence highlighting the different functions of nuclear and mitochondrial HER4.
Tovey
Sian M
SM
Endocrine Cancer Group, Section of Surgical and Translational Research, Glasgow University, UK.
Dunne
Barbara
B
Witton
Caroline J
CJ
Cooke
Timothy G
TG
Bartlett
John M S
JM
D000906:Antibodies; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D002467:Cell Nucleus / Q000473:pathology; D066246:ErbB Receptors / Q000032:analysis* / Q000276:immunology*; D005110:Extracellular Space / Q000201:enzymology* / Q000276:immunology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D042541:Intracellular Space / Q000201:enzymology* / Q000276:immunology; D008928:Mitochondria / Q000473:pathology; D020411:Oligonucleotide Array Sequence Analysis; D066247:Receptor, ErbB-4
D000906:Antibodies; C587689:ERBB4 protein, human; D066246:ErbB Receptors; D066247:Receptor, ErbB-4